Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Mesa Verde Venture Partners

Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Read the press release here: https://loom.ly/1Pu09G0

#cancertreatment #biopharma #sciencenews

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Read the press release here: https://loom.ly/4PQGN9c

#science #biopharma #cancertreatment #multiplemyeloma #car-t

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Read the press release here: https://loom.ly/HCKoAzU

#cancertreatment #science #biopharma

Immix Biopharma is pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ 

Read more here: https://lnkd.in/emdDgvbQ

#science #cancertreatment #technology

Immix Biopharma's subsidiary Nexcella, Inc. 

Learn more about Nexcella, Inc.: https://nexcella.com/  

#biopharma #cancertreatment #science

Who founded Immix Biopharma?

Read more here: https://lnkd.in/enZ6FH3s 

#science #cancer #biopharma

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

#healthcare #science #biopharma

Dr. Suzanne Lentzsch Joins Immix Biopharma Scientific Advisory Board

Read the press release here: https://loom.ly/spWfYjU

#sciencenews #biopharma

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for the following: 

Read the press release here: https://loom.ly/fwrLYNQ

#fda #science #cancer

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Read the press release here: https://loom.ly/fwrLYNQ 

#science #biopharma #sciencenews

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover				-6.00 -
cash per share	0.09 -	0.04 48.74%	4.80 10,679.57%	0.97 79.86%	1.01 4.36%
company equity multiplier	-0.26 -	-0.11 55.89%	1.01 986.53%	1.13 12.03%	1.21 7.21%
days of inventory outstanding
days of payables outstanding					95.66K -
days of sales outstanding				-1.04 -
dividend yield
ebit per revenue				0.09 -
ebt per ebit	1.13 -	2.49 120.34%	18.03 623.98%	1.00 94.45%	0.96 3.54%
effective tax rate	-0.02 -	-0.02 28.07%	-0.00 98.41%	-0.00 406.46%	-0.00 35.81%
enterprise value multiple	-40.84 -	-79.63 94.99%	3.35 104.21%	-2.24 166.73%	-6.35 184.21%
fixed asset turnover				-25.15K -
free cash flow per share	-0.09 -	-0.05 51.17%	-0.43 838.78%	-0.53 23.21%	-0.66 23.49%
gross profit margin				1 -
interest coverage	-7.66 -	-4.45 41.90%	-7.52 68.91%	-16.54K 219,886.66%
inventory turnover
long term debt to capitalization
net income per ebt	1.02 -	1.02 0.59%	1.00 1.50%	1.00 0.10%	0.99 1.04%
net profit margin				0.09 -
operating cash flow per share	-0.09 -	-0.05 50.71%	-0.43 838.31%	-0.53 23.27%	-0.66 22.92%
operating profit margin				0.09 -
payables turnover					0.00 -
pretax profit margin				0.09 -
price fair value	-8.50 -	-6.81 19.89%	0.73 110.68%	2.42 232.52%	7.31 202.69%
receivables turnover				-350.08 -
return on assets	-1.03 -	-2.13 106.19%	-1.34 36.99%	-0.55 58.81%	-0.77 40.25%
return on capital employed	0.23 -	0.10 58.48%	-0.08 178.33%	-0.60 702.08%	-1.00 65.25%
return on equity	0.27 -	0.24 9.05%	-1.36 658.59%	-0.63 53.86%	-0.94 50.36%
total debt to capitalization	9.04 -	-6.50 171.94%	0.00 100.04%

NASDAQ:IMMX

Immix Biopharma, Inc.

Last Close

2.15

26/07 20:00

Market Cap

53.89M

Beta: -

Volume Today

125.04K

Avg: 208.58K

PE Ratio

−4.23

PFCF: −5.01

Preview